Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDIX HER2: Neoadjuvant Kadcyla vs Docetaxel/Trastuzumab/Pertuzumab in HER2+ Breast Cancer
NCT02568839Phase 3Active, not recruiting
- Start
- Nov 2014
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab emtansine in HER2-positive breast cancer. Started Nov 2014; status: active, not recruiting.
02
Drugs
trastuzumab emtansine
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT02568839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02568839.